Colchicine is used to treat and prevent gout attacks, a painful condition caused by uric acid crystals in the joints. It is also used to treat familial Mediterranean fever, a rare inherited inflammatory condition.[2] Colcrys is currently approved and in use across 66 indications[4].[1]
Colcrys is one of 816 small molecule programs targeting Cerebral Amyloid Angiopathy. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Patents
Pipeline
Competition
332 competitors in Treatment
Colcrys
Biltricide
Levulan
Theo-Dur
Minipress
Niclocide
Alfenta
Emtriva
Lamprene
Foscavir
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Jul 29, 2009
COLCRYS
NDA NDA022352
Sep 26, 2014
MITIGARE
NDA NDA204820
Jan 30, 2019
GLOPERBA
NDA NDA210942
Jun 16, 2023
LODOCO
NDA NDA215727
Sources
Details
Patent Cliff
Oct 6, 2028
Earliest patent expiration — generic entry possible after this date